Taiwan divestment another step in Eisai's manufacturing shake-out
This article was originally published in Scrip
Eisai's decision to divest its production facility in Taiwan forms part of the Japanese firm's wider effort to restructure its global manufacturing operations to align with changing demand and to control costs amid broader revenue pressures.
You may also be interested in...
While it has raised the full-year profit outlook, Takeda came in under analysts' consensus for some of its fiscal first-half figures, pointing to a growing forex impact.
Product review report reveals multiple delays and missteps on route to market, holding valuable lessons for other gene therapy developers but also evidencing an ultimately welcoming environment.
Join us for a quick audio roundup of major developments in the international biopharma industry over the past week, as covered by Scrip's global team.